Tauroursodeoxycholic acid administration as adjuvant therapy in cirrhotic patients on transplantation waiting lists
- PMID: 11020875
Tauroursodeoxycholic acid administration as adjuvant therapy in cirrhotic patients on transplantation waiting lists
Abstract
Background/aims: The lack of organ availability and an increased number of end-stage cirrhotic patients has led to the lengthening of liver transplantation waiting lists. The progressive worsening of clinical and functional performance in patients awaiting the graft is one of the factors implicated in the increased mortality during the wait and in poor transplantation outcome. In this work our aim was to evaluate the effects of tauroursodeoxycholic acid administration on biochemical, clinical and functional parameters in a group of cirrhotic patients consecutively placed onto our liver transplantation waiting list.
Methodology: Ten cirrhotic patients underwent biochemical, clinical and functional evaluation at the time of entering on our liver transplantation waiting list, then tauroursodeoxycholic acid was administered until liver transplantation. Complete evaluation was repeated every 2 months. The results were compared to those of a comparable historical control group that had undergone liver transplantation the year before the study.
Results: All patients were transplanted within 6 months from insertion on the waiting list. Longitudinal analysis of the treated group showed that cholestasis and cytolisis parameters constantly decreased and that gamma-glutamyl transpeptidase was significantly lower compared to baseline values at the 4th month of therapy. Clinical and functional parameters remained stable during follow-up. Comparison with the control group showed that gamma-glutamyl transpeptidase, alkaline phosphatase and both aminotransferases were reduced at the 4th month of therapy. Fewer days of hospital stay and less intensive care were required in the treated group.
Conclusions: Treatment of end-stage cirrhotic patients awaiting liver transplantation with tauroursodeoxycholic acid improves biochemical parameters of cytolisis and cholestasis, and furthermore helps to maintain clinical and functional stability during the wait. Improved biochemical conditions and steady clinical-functional performance may promote better short-term transplant outcome.
Similar articles
-
One-year pilot study on tauroursodeoxycholic acid as an adjuvant treatment after liver transplantation.Ital J Gastroenterol Hepatol. 1999 Aug-Sep;31(6):462-8. Ital J Gastroenterol Hepatol. 1999. PMID: 10575563 Clinical Trial.
-
Analysis of Model for End-Stage Liver Disease (MELD) score in a liver transplantation waiting list.Transplant Proc. 2007 Oct;39(8):2511-3. doi: 10.1016/j.transproceed.2007.07.023. Transplant Proc. 2007. PMID: 17954160
-
Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation.Hepatogastroenterology. 2003 Nov-Dec;50(54):1753-5. Hepatogastroenterology. 2003. PMID: 14696397
-
The impact of nutrition on cirrhotic patients awaiting liver transplantation.Curr Opin Clin Nutr Metab Care. 2010 Sep;13(5):554-61. doi: 10.1097/MCO.0b013e32833b64d2. Curr Opin Clin Nutr Metab Care. 2010. PMID: 20531175 Review.
-
Mortality on the waiting list for liver transplantation: management and prioritization criteria.Transplant Proc. 2011 Apr;43(3):687-9. doi: 10.1016/j.transproceed.2011.01.106. Transplant Proc. 2011. PMID: 21486574 Review.
Cited by
-
Bile acid therapy for primary biliary cholangitis: Pathogenetic validation.World J Exp Med. 2025 Mar 20;15(1):101771. doi: 10.5493/wjem.v15.i1.101771. eCollection 2025 Mar 20. World J Exp Med. 2025. PMID: 40115760 Free PMC article. Review.
-
Effects of cyclic parenteral nutrition on parenteral-associated liver dysfunction parameters.Nutr J. 2017 Oct 4;16(1):66. doi: 10.1186/s12937-017-0289-7. Nutr J. 2017. PMID: 28978317 Free PMC article.
-
Efficacy and safety of tauroursodeoxycholic acid in the treatment of liver cirrhosis: a double-blind randomized controlled trial.J Huazhong Univ Sci Technolog Med Sci. 2013 Apr;33(2):189-194. doi: 10.1007/s11596-013-1095-x. Epub 2013 Apr 17. J Huazhong Univ Sci Technolog Med Sci. 2013. PMID: 23592128 Clinical Trial.
-
Tauroursodeoxycholic acid dampens oncogenic apoptosis induced by endoplasmic reticulum stress during hepatocarcinogen exposure.Oncotarget. 2015 Sep 29;6(29):28011-25. doi: 10.18632/oncotarget.4377. Oncotarget. 2015. PMID: 26293671 Free PMC article.
-
Lipid signaling and lipotoxicity in metaflammation: indications for metabolic disease pathogenesis and treatment.J Lipid Res. 2016 Dec;57(12):2099-2114. doi: 10.1194/jlr.R066514. Epub 2016 Jun 21. J Lipid Res. 2016. PMID: 27330055 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Medical